Evidence map›Paper›PMID 34804821›Full record

ArticleTranslational andrology and urology2021

ISPRF: a machine learning model to predict the immune subtype of kidney cancer samples by four genes.

Zhifeng Wang, Zihao Chen, Hongfan Zhao, Hao Lin, Junjie Wang, Ning Wang, Xiqing Li, Degang Ding

Open access · diamondAbstract read
In one paragraph

Article in Translational andrology and urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Zhifeng Wang *Department of Urology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, China.
Zihao Chen *Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Hongfan ZhaoDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Hao LinDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Junjie WangDepartment of Urology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, China.
Ning WangDepartment of Urology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, China.
Xiqing LiDepartment of Oncology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, China.
Degang DingDepartment of Urology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, China.
Zhengzhou University · CNHenan Provincial People's Hospital · CNNanfang Hospital · CNSouthern Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClear cell renal cell carcinoma (ccRCC) is the most common type of renal cell carcinoma (RCC). Immunotherapy, especially anti-PD-1, is becoming a pillar of ccRCC treatment. However, precise biomarkers and robust models are needed to select the proper patients for immunotherapy.

methodsA total of 831 ccRCC transcriptomic profiles were obtained from 6 datasets. Unsupervised clustering was performed to identify the immune subtypes among ccRCC samples based on immune cell enrichment scores. Weighted correlation network analysis (WGCNA) was used to identify hub genes distinguishing subtypes and related to prognosis. A machine learning model was established by a random forest (RF) algorithm and used on an open and free online website to predict the immune subtype.

resultsIn the identified immune subtypes, subtype2 was enriched in immune cell enrichment scores and immunotherapy biomarkers. WGCNA analysis identified four hub genes related to immune subtypes, CTLA4, FOXP3, IFNG, and CD19. The RF model was constructed by mRNA expression of these four hub genes, and the value of area under the receiver operating characteristic curve (AUC) was 0.78. Subtype2 patients in the independent validation cohort had a better drug response and prognosis for immunotherapy treatment. Moreover, an open and free website was developed by the RF model (https://immunotype.shinyapps.io/ISPRF/).

conclusionsThe current study constructs a model and provides a free online website that could identify suitable ccRCC patients for immunotherapy, and it is an important step forward to personalized treatment.

Indexed as

immune subtypesmachine learningonline websiteRenal cell carcinoma (RCC)

Identifiers

PMID34804821
PMCPMC8575581
OpenAlexW3126318325

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.